Ketorolac eyedrops and ranibizumab combo reduces CMT

A combination of ketorolac eyedrops 0.45% and intravitreal ranibizumab reduces central macular thickness (CMT) in choroidal neovascularisation (CNV), reveals a recent paper.

Dr Andrea Russo et al., Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Italy, conducted a pilot study on 56 patients who were randomized to receive the combination treatment (group 1) or ranibizumab alone (group 2).

All patients were administered monthly 0.5 mg ranibizumab injections for 3 months and in accordance with standard of care thereafter. Group 1 patients self-administered one drop of ketorolac three times a fay for six months and all patients underwent six months follow-up.

At the six-month follow-up both groups demonstrated a significant improvement in best-corrected visual acuity. The mean six-month change in CMT was −124 µm and −86.9 µm in groups 1 and 2, respectively. The combo group’s change in CMT was greater than the ranibizumab-only group. The combo treatment presented no adverse effects.

The combo treatment was found to be safe effective for reducing CMT. Topical ketorolac could actually supplement the activity of intravitreal ranibizumab in reducing CMT in CNV.

The abstract can be viewed in the British Journal of Ophthalmology.